在ChAdOx1-S/BNT162b2疫苗接种方案中，第三剂mRNA疫苗针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的免疫原性。
Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants.
作者信息
García-Pérez Javier, Borobia Alberto M, Pérez-Olmeda Mayte, Portolés Antonio, Castaño Luis, Campins-Artí Magdalena, Bertrán María Jesús, Bermejo Mercedes, Arribas José Ramón, López Andrea, Ascaso-Del-Rio Ana, Arana-Arri Eunate, Fuentes Camps Inmaculada, Vilella Anna, Cascajero Almudena, García-Morales María Teresa, Castillo de la Osa María, Pérez Ingidua Carla, Lora David, Jiménez-Santana Paloma, Pino-Rosa Silvia, Gómez de la Cámara Agustín, De La Torre-Tarazona Erick, Calonge Esther, Cruces Raquel, Belda-Iniesta Cristóbal, Alcamí José, Frías Jesús, Carcas Antonio J, Díez-Fuertes Francisco
机构信息
Unidad de Inmunopatología del SIDA, Centro Nacional de Microbiología, Instituto de Salud Carlos III (ISCIII), Majadahonda, 28222 Madrid, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Majadahonda, 28222 Madrid, Spain.
出版信息
iScience. 2024 Aug 14;27(9):110728. doi: 10.1016/j.isci.2024.110728. eCollection 2024 Sep 20.
CombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 days after a third dose of a mRNA vaccine, in subjects that received a previous prime-boost scheme with ChAdOx1-S/BNT162b2. Secondary outcomes extended the study to 3 and 6 months. The third vaccine dose of mRNA-1273 in naive participants previously vaccinated with ChAdOx1-S/BNT162b2 regimen reached higher neutralizing antibodies titers against the variants of concern Delta and BA.1 lineage of Omicron compared with those receiving a third dose of BNT162b2 at day 28. These differences between BNT162b2 and mRNA-1273 arms were observed against the ancestral variant G614 at day 90. Suboptimal neutralizing response was observed against BQ.1.1, XBB.1.5/XBB.1.9, and JN.1 in a relevant proportion of individuals 180 days after the third dose, even after asymptomatic Omicron breakthrough infections. EudraCT (2021-001978-37); ClinicalTrials.gov (NCT04860739).
CombiVacS研究表明，异源ChAdOx1-S/BNT162b2疫苗组合具有强烈的免疫反应。该研究的主要结果是评估在接受过ChAdOx1-S/BNT162b2初免-加强方案的受试者中，在第三剂mRNA疫苗接种28天后，针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的体液免疫反应。次要结果将研究延长至3个月和6个月。与在第28天接受第三剂BNT162b2的受试者相比，先前接种过ChAdOx1-S/BNT162b2方案的初免参与者接种第三剂mRNA-1273后，针对关注变体Delta和奥密克戎BA.1谱系的中和抗体滴度更高。在第90天，观察到BNT162b2组和mRNA-1273组在针对原始变体G614方面存在这些差异。在第三剂接种180天后，相当一部分个体对BQ.1.1、XBB.1.5/XBB.1.9和JN.1的中和反应欠佳，即使在无症状奥密克戎突破性感染后也是如此。欧洲临床试验数据库编号（EudraCT）：2021-001978-37；美国国立医学图书馆临床试验注册中心编号（ClinicalTrials.gov）：NCT04860739。
Zotero 插件